Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1637 1642 1643 1644 1646
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17927529 | BISPECIFIC MOLECULES FOR SELECTIVELY MODULATING T CELLS | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17773283 | DEGRADATION OF SURFACE PROTEINS USING BISPECIFIC BINDING AGENT | Non-Final OA | The Regents of the University of California |
| 18560746 | CHIMERIC POLYPEPTIDES AND METHODS OF USE | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18066529 | PROTEASE-ACTIVATED T CELL BISPECIFIC ANTIBODIES | Non-Final OA | Hoffmann-La Roche Inc. |
| 18481725 | COMPOSITIONS AND METHODS OF TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS TARGETING CLAUDIN 18.2 | Non-Final OA | MEDIMMUNE, LLC |
| 17770304 | Immunotherapy Targeting Tumor Neoantigenic Peptides | Final Rejection | INSERM (Institut National de la Santé et de la Recherche Médicale) |
| 18285634 | CHIMERIC ANTIGEN RECEPTOR COMPRISING AN ANTI-CD19 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND NATURAL KILLER CELLS COMPRISING THE SAME | Non-Final OA | GC Cell Corporation |
| 17789079 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS BY TARGETING IGSF8 | Non-Final OA | GV20 Therapeutics LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy